BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hunter LA, Soares HP. Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:5074. [PMID: 34680223 DOI: 10.3390/cancers13205074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Jin S, Zhao R, Zhou C, Zhong Q, Shi J, Su C, Li Q, Su X, Chi H, Lu X, Jiang G, Chen R, Han J, Jiang M, Qiao S, Liu J, Song M, Song L, Du Y, Chang Z, Wang M, Dong M, Zhong Y, Yu P, Zhang X, Zong H. Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial. Int J Cancer 2023;152:1648-58. [PMID: 36444498 DOI: 10.1002/ijc.34372] [Reference Citation Analysis]
2 Parasuraman S, Thiel E, Park J, Teschemaker A. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation. J Med Econ 2023;:1-12. [PMID: 36883994 DOI: 10.1080/13696998.2023.2187604] [Reference Citation Analysis]
3 Zhang J, Zhan Y, Chen J, Kang D, Xiang R, Zhang R, Zhang Y, Pu Y, Zhang J, Zhang L, Huang Y, Gong R, Su X, Nie Y, Shi Q. Development of a Patient-Reported Symptom Item Bank for Patients with Hepatobiliary or Pancreatic Malignancies: A Systematic Review. Patient Prefer Adherence 2023;17:199-207. [PMID: 36698859 DOI: 10.2147/PPA.S398666] [Reference Citation Analysis]
4 Andersen LB, Mahler MSK, Andersen RF, Jensen LH, Raunkilde L. The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab. Cancers (Basel) 2022;14. [PMID: 36230519 DOI: 10.3390/cancers14194598] [Reference Citation Analysis]
5 Chen VW, Portuondo JI, Cooper Z, Massarweh NN. Use of Palliative Interventions at End of Life for Advanced Gastrointestinal Cancer. Ann Surg Oncol 2022. [PMID: 35947309 DOI: 10.1245/s10434-022-12342-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li D, Zhang YH, Crook CJ, Iyer RV. Updates in Biliary Tract Cancers. Cancers (Basel) 2022;14:2746. [PMID: 35681726 DOI: 10.3390/cancers14112746] [Reference Citation Analysis]
7 Lurje I, Czigany Z, Eischet S, Bednarsch J, Ulmer TF, Isfort P, Strnad P, Trautwein C, Tacke F, Neumann UP, Lurje G. The prognostic impact of preoperative body composition in perihilar and intrahepatic cholangiocarcinoma. Hepatol Commun 2022. [PMID: 35616275 DOI: 10.1002/hep4.2004] [Reference Citation Analysis]
8 Chen Q, Lu J, Lu X, Yao X, Zhang X, Wang S, Guo J. The Prognostic Value of Sarcopenia and Myosteatosis in Biliary Tract Cancer After Palliative Treatment With Radiation-Emitting Metallic Stent. Front Surg 2022;9:852137. [DOI: 10.3389/fsurg.2022.852137] [Reference Citation Analysis]